More Cities in the Democratic Republic of the Congo to Get Satellite-Enabled High-Speed Connectivity with SES Networks and Gilat Telecom
SES Networks’ longtime customer in the Democratic Republic of the Congo (DRC), Gilat Telecom, has expanded the satellite capacity under contract with SES Networks in the country, now topping more than 3.0 Gbps.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170907006892/en/
More Cities in the Democratic Republic of the Congo to Get Satellite-Enabled High-Speed Connectivity with SES Networks and Gilat Telecom (Photo: Business Wire)
Gilat has been providing Kinshasa, the capital and largest city in DRC, with expansive internet connectivity services for many years, and has seen unprecedented network reliability and resiliency from the SES Networks service. The company has now also launched service over SES’s O3b Medium Earth Orbit (MEO) satellite fleet to a second DRC location, bringing fiber-equivalent internet to customers in Lubumbashi.
Gilat Telecom is based in Israel, and offers satellite and fiber-based connectivity services in Africa, Asia and the Middle East. Gilat first deployed SES Networks’ ultra-low latency, high throughput connectivity in 2014, following the launch of the first four satellites in the O3b Medium Earth Orbit (MEO) fleet, becoming the first to use the new connectivity in Africa, and the second worldwide. Since that time, Gilat has seen strong and steady customer growth in DRC as customers have responded to the high-performance internet service and the applications it enables, and has effectively become one of the largest MEO satellite solutions users in the world.
As the need for reliable connectivity has expanded in DRC, SES Networks worked with Gilat to implement a diverse routing solution to further increase network uptime and availability. With this solution, ground terminals were placed in multiple locations throughout the region, and an advanced intelligent routing platform was implemented to enable intelligent switching across multiple satellite links resulting in extremely high link availability.
“For years, improving connectivity has been a high priority for us and we have been incredibly impressed with the speed and quality of our service through SES Networks,” said Dan Zajicek, CEO of Gilat Telecom. “We chose SES Networks’ MEO Satellites because of its unique ability to rival fiber performance, without having to rely on any land-based link from a neighbouring country. We look forward to many more years of partnership with SES Networks, and leveraging the company’s unrivalled breadth of connectivity solutions to expand the reach of internet and mobile connectivity in DRC.”
“We are proud to celebrate this milestone of three years of service with Gilat,” said Carole Kamaitha, Vice President of Africa Sales at SES Networks. “Our shared commitment to expanding and improving connectivity has enabled us to break through barriers together, and design creative and unique solutions for DRC. Moving forward, we are eager to work even more with Gilat, leveraging the diverse capabilities of SES Networks for the benefit of customers in Kinshasa, Lubumbashi and across DRC.”
Follow us on:
SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in two key business units: SES Video and SES Networks. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions. SES’s portfolio includes ASTRA, O3b and MX1, a leading media service provider that offers a full suite of innovative digital video and media services. SES is listed on the Euronext Paris and Luxembourg Stock Exchange (ticker: SESG). Further information available at: www.ses.com
Gilat Telecom is a managed service provider that offers connectivity solutions together with other value-added services in Africa, Asia, and the Middle East.
With successful deployments in 50 countries worldwide, Gilat Telecom consistently delivers high-quality, cost-effective and efficient solutions to telcos, ISPs, governments, enterprise customers and international organizations.
The company operates three international teleports in Europe and the Middle East, multiple hubs/PoPs in Africa, Europe and the US.
In addition, Gilat Telecom is a shareholder in WIOCC, owners of the East African Submarine System (EASSy), and in the West Africa Cable System (WACS), with undersea fibre-optic cable systems connecting eastern and western Africa to the rest of the world.
Gilat Telecom also provides space segments over numerous satellites including Intelsat, Telesat, Hellas Sat, ABS, SES NewSkies and others.
Gilat Telecom is a subsidiary of The Eurocom Group.
For more information, please visit www.gilat.net
Corporate Communications & PR
Tel. +352 710 725 500
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31 | Pressemelding
Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00 | Pressemelding
AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20 | Pressemelding
AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute
Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11 | Pressemelding
The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other
Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 16:20 | Pressemelding
Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to
Ncardia Announces Completion of €10.5M Investment Round17.11.2017 12:31 | Pressemelding
Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom